Progression of nephropathy in type 2 diabetic patients.

BACKGROUND Nephropathy in type 2 diabetes is the single most common cause of end-stage renal disease (ESRD), but the decline in kidney function varies considerably between individuals, and determinants of renal function loss, early in the course of renal disease, have not been clearly identified. METHODS In a prospective observational study, we followed 227 (60 female) Caucasian type 2 diabetic patients with nephropathy for 6.5 (range 3 to 17) years from a baseline glomerular filtration rate (GFR) of 83 (SD30) mL/min/1.73m(2) with 7 (range 3 to 22) measurements of GFR ((51)Cr-EDTA) per patient. We evaluated determinants of (1) rate of decline in GFR, (2) risk of doubling in serum creatinine or ESRD, and (3) mortality using potential risk factors at baseline and during follow-up. RESULTS The mean (SD) rate of decline in GFR was 5.2 (4.1) mL/min/year. In multivariate regression analysis, higher baseline albuminuria, systolic blood pressure (SBP), hemoglobin A1c, GFR, age, and degree of diabetic retinopathy were significantly associated with increased rate of decline in GFR (R(2) (adj) 0.24). During follow-up, elevated mean albuminuria, SBP, hemoglobin A1c, and lower hemoglobin, heavy smoking, and presence of diabetic retinopathy were significantly associated with increased decline in GFR (R(2) (adj) 0.26). During follow-up, 63 patients had a doubling in serum creatinine or developed ESRD, and 79 patients died, primarily due to cardiovascular disease. In Cox regression analysis, higher baseline albuminuria, hemoglobin A1c, and SBP, together with lower GFR and hemoglobin, were significantly associated with shorter time to doubling of serum creatinine or ESRD. Higher baseline albuminuria, hemoglobin A1c, SBP, and age were significantly associated with increased mortality. CONCLUSION Our long-term prospective study of type 2 diabetic patients with nephropathy has revealed several modifiable risk factors of enhanced progression in kidney disease and increased mortality.

[1]  Merlin C. Thomas,et al.  Unrecognized anemia in patients with diabetes: a cross-sectional survey. , 2003, Diabetes care.

[2]  H. Parving,et al.  The course of kidney function in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy , 1993, Diabetologia.

[3]  H. Parving.  Renoprotection in diabetes: genetic and non-genetic risk factors and treatment , 1998, Diabetologia.

[4]  A. Levey,et al.  Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. , 1991, Journal of the American Society of Nephrology : JASN.

[5]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[6]  B. Brenner,et al.  The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. , 2003, Kidney international.

[7]  A. Xu,et al.  Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. , 2004, The Journal of clinical endocrinology and metabolism.

[8]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[9]  M. Wulster-Radcliffe,et al.  Adiponectin differentially regulates cytokines in porcine macrophages. , 2004, Biochemical and biophysical research communications.

[10]  S. Fukumoto,et al.  Factors affecting progression of renal failure in patients with type 2 diabetes. , 2003, Diabetes care.

[11]  G. Pacini,et al.  Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. , 2000, Diabetes.

[12]  H. Lodish,et al.  Role of Disulfide Bonds in Acrp30/Adiponectin Structure and Signaling Specificity , 2003, Journal of Biological Chemistry.

[13]  H. Parving,et al.  Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  R. Paschke,et al.  Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. , 2002, Biochemical and biophysical research communications.

[15]  Sunil V. Rao,et al.  Management of glomerular proteinuria: a commentary. , 2003, Journal of the American Society of Nephrology : JASN.

[16]  R. Nagai,et al.  Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. , 2004, Biochemical and biophysical research communications.

[17]  G. Beck,et al.  Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. , 1996, The New England journal of medicine.

[18]  H. Parving,et al.  Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. , 2000, Kidney international.

[19]  Y. Akasaka,et al.  Changes in the distribution pattern of gelatin‐binding protein of 28 kDa (adiponectin) in myocardial remodelling after ischaemic injury , 2003, Histopathology.

[20]  T. Jørgensen,et al.  Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. , 2003, Diabetes care.

[21]  U. Müller-Ladner,et al.  Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[22]  O. Tomonaga,et al.  Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients , 1997, Diabetologia.

[23]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[24]  H. Nagaraja,et al.  Urine chemokines as biomarkers of human systemic lupus erythematosus activity. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  S. Kihara,et al.  Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. , 2003, Kidney international. Supplement.

[26]  Pedro Iglesias,et al.  The role of the novel adipocyte-derived hormone adiponectin in human disease. , 2003, European journal of endocrinology.

[27]  A. Tiengo,et al.  Concomitance of diabetic retinopathy and proteinuria accelerates the rate of decline of kidney function in type 2 diabetic patients. , 2002, Diabetes care.

[28]  H. Parving,et al.  Glomerular structure and function in proteinuric Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[29]  G. Jerums,et al.  Treatment of Hypertension in Diabetes , 1996, Diabetes Care.

[30]  S. Kihara,et al.  Adiponectin Specifically Increased Tissue Inhibitor of Metalloproteinase-1 Through Interleukin-10 Expression in Human Macrophages , 2004, Circulation.

[31]  L. Balant,et al.  The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. , 1982, Kidney international.

[32]  S. Klahr.  Assessing the Progression of Renal Disease , 1996 .

[33]  Mai-Szu Wu,et al.  Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  J. Bröchner-Mortensen,et al.  Selection of routine method for determination of glomerular filtration rate in adult patients. , 1976, Scandinavian journal of clinical and laboratory investigation.

[35]  C. Hasslacher,et al.  Effect of metabolic factors and blood pressure on kidney function in proteinuric Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[36]  J. Nerup,et al.  Rapid changes in chromatographically determined haemoglobin A1c induced by short-term changes in glucose concentration , 1980, Diabetologia.

[37]  T. Funahashi,et al.  Plasma adiponectin concentration before and after successful kidney transplantation. , 2003, Transplantation proceedings.

[38]  H. Parving,et al.  Albuminuria and Poor Glycemic Control Predict Mortality in NIDDM , 1995, Diabetes.

[39]  E. Ritz,et al.  Similar risks of nephropathy in patients with type I or type II diabetes mellitus. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  A. Vaag,et al.  Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients , 1991, Diabetologia.

[41]  K. Borch-Johnsen,et al.  Albuminuria reflects widespread vascular damage , 1989, Diabetologia.

[42]  G. Remuzzi,et al.  Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? , 1990, Kidney international.

[43]  B. Feldt-Rasmussen,et al.  Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. , 1985, Scandinavian journal of clinical and laboratory investigation.

[44]  J. Christiansen,et al.  Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. , 2009, Acta medica Scandinavica.

[45]  E. Lewis,et al.  Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[47]  S. Klahr.  The modification of diet in renal disease study. , 1989, The New England journal of medicine.

[48]  Joni K. Evans,et al.  Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. , 1996, Kidney international.

[49]  Hui Chen,et al.  Adiponectin Stimulates Production of Nitric Oxide in Vascular Endothelial Cells* , 2003, Journal of Biological Chemistry.

[50]  M. Kakei,et al.  Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. , 2004, Biochemical and biophysical research communications.

[51]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[52]  K. Larsen.  Creatinine assay by a reaction-kinetic principle. , 1972, Clinica chimica acta; international journal of clinical chemistry.

[53]  E. Ritz,et al.  How should we manage anaemia in patients with diabetes? , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[55]  D. Wesson,et al.  Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[56]  F. Martin,et al.  Clinical and Histological Correlations of Decline in Renal Function in Diabetic Patients With Proteinuria , 1994, Diabetes.

[57]  J. Christiansen.  Cigarette Smoking and Prevalence of Microangiopathy in Juvenile-Onset Insulin-dependent Diabetes Mellitus , 1978, Diabetes Care.

[58]  J. Zazgornik,et al.  Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[59]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[60]  B. Brenner,et al.  Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. , 2003, Archives of internal medicine.

[61]  T. Funahashi,et al.  Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  C. Mogensen,et al.  Radioimmunoassay for urinary albumin using a single antibody. , 1970, Scandinavian journal of clinical and laboratory investigation.

[63]  Stephen MacMahon,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies , 2001, The Lancet.

[64]  H. Parving,et al.  Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[65]  H. Parving,et al.  Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. , 1992, Kidney international.

[66]  Mark E Molitch,et al.  Nephropathy in diabetes. , 2004, Diabetes care.

[67]  T Nakamura,et al.  An Adipocyte-Derived Plasma Protein, Adiponectin, Adheres to Injured Vascular Walls , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[68]  E. Lewis,et al.  Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[69]  H. Parving,et al.  Progression of diabetic nephropathy. , 2001, Kidney international.

[70]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[71]  J. Fernández-Real,et al.  Novel interactions of adiponectin with the endocrine system and inflammatory parameters. , 2003, The Journal of clinical endocrinology and metabolism.

[72]  T. Greene,et al.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. , 1995, Annals of internal medicine.

[73]  K. Takahashi,et al.  Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. , 2001, Biochemical and biophysical research communications.

[74]  C. Mogensen,et al.  Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. , 1984, The New England journal of medicine.

[75]  F. Lönnqvist,et al.  Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. , 2004, Kidney international.